Erasca touts early colorectal cancer data, trims a slate of trials and preclinical programs to refine focus
Erasca believes it’s secured the early clinical data to show one of its targeted therapies holds promise as a “backbone” for drug combinations, particularly for colorectal cancer. But to get there, the biotech is chopping a string of combo trials and other discovery-stage programs to narrow its focus.
Gone are three trials pairing ERAS-007 with different drugs (two approved, one experimental from Erasca’s own pipeline) in various cancer types; a trial for a KRAS G12C inhibitor “due to increasingly competitive landscape for small- and mid-cap biopharma companies”; and three preclinical candidates hitting SOS1, MYC and RAS, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.